New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:54 EDTHEBHemispherx wins federal lawsuit regarding investment banking fees
Hemispherx Biopharma announced after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6M for commissions from private sales of stock in 2009. MidSouth Capital, sued Hemispherx in 2010 for commissions it claimed it was due under the terms of a 2008 contract which Hemispherx never signed. Investment bank Rodman & Renshaw sold more than $31M worth of Hemispherx stock in mid-2009. Rodman & Renshaw was promptly paid the commission it was due under the terms of its engagement agreement. MidSouth, whose brokers, Rob Rosenstein and Adam Cabibi, were terminated after they failed to secure a closing on several failed convertible debenture proposals, also demanded payment of a commission on the subsequent Rodman & Renshaw stock sale.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
09:20 EDTHEBOn The Fly: Pre-market Movers
Subscribe for More Information
September 30, 2014
18:36 EDTHEBOn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTHEBCDC confirms first U.S. patient diagnosed with Ebola virus
Subscribe for More Information
17:57 EDTHEBHemispherx up 12% after hours following CDC confirmation of Ebola case in U.S.
September 29, 2014
08:35 EDTHEBHemispherx expands research on potential Ebola treatments
Hemispherx Biopharma announced a widened set of research collaborations designed to develop therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation. The rapid acquisition of Ebola virus, or EBOV, sequence variation has been recently demonstrated during genomic surveillance of the current Ebola virus disease, or EVD. This observed genomic sequence variation suggests drugs that target specific viral non-variant protein sequences are at risk of mutation mediated activity failure. This complicates significantly the development of EBOV inhibitors in the drug development pipeline, some of which have been highly effective in treating advanced EVD in non-human primates. The two platform drugs of Hemispherx, Alferon N and Ampligen, have certain unique structural attributes and developmental histories which suggest potential incremental value with respect to inclusion in various Ebola therapeutic cocktails under development. First, both drugs have mechanisms of action, which are multifaceted by working thru cellular "molecular cascades" rather than target viral targets whose specificity is vulnerable to mutational change.
September 22, 2014
08:49 EDTHEBHemispherx announces Alferon LDO primate research peer-reviewed publication
Hemispherx Biopharma announced a peer-reviewed publication entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus by Low Dose Natural Human IFN- Administered to the Buccal Mucosa" in the current issue of Antiviral Research 2014. This publication is a collaborative project conducted at Viroclinics Biosciences BV, Rotterdam, an internationally recognized research facility for the study of influenza viruses. The biohazard laboratories are directed by Prof. Albert D. M. E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza. Highly pathogenic avian influenza A virus is endemic in wild birds in Asia and the Middle East, causing disease and transmissibility in domestic poultry. Infection of humans with H5N1 is associated with a high mortality rate due to an alveolar destructive primary viral pneumonia frequently expressed clinically as acute respiratory distress syndrome.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use